Clinical trials: Diffuse Large B-cell-lymphoma
Diffuse Large B Cell Lymphoma
ZR-CHOP in DLBCL With Specific Gene Abnormality
This is a phase 2, single center clinical trial. to evaluating the efficacy and safety of Zanubrutinib in combination with R-CHOP in newly diagnosed diffuse large B-cell lymphoma with specific gene abnormality.
- Trial name
- NCT05290337
- Testing
- zanubrutinib
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Fudan University
Lymphoma,Non-Hodgkin, Diffuse Large B Cell Lymphoma
The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas
The purpose of this study is to determine whether the CD16- monocyte/CD16+ monocyte ratio could help predict the prognosis of DLBCL and PTCL.
- Conditions
- Lymphoma,Non-Hodgkin, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
- Trial name
- NCT03000738
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Diffuse Large B Cell Lymphoma
Imaging Apoptosis for Lymphoma Treatment Response
Apoptosis is a specific form of cell death that leads to clearance of dead cells without causing inflammation or injury to normal adjacent tissues.
- Trial name
- NCT05048732
- Testing
- 18F-FluorApoTrace
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Diffuse Large B Cell Lymphoma
Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?
CAR-T cell therapy has improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL R/R). However, only 65% of patients achieve a complete metabolic response after this treatment.
- Trial name
- CARTROG (NCT06352242)
- Testing
- Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients, Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers
- Where
- 2 sites in France
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of venetoclax when given together with carmustine, etoposide, cytarabine, and melphalan before stem cell transplant in treating participants with non-Hodgkin lymphoma…
- Conditions
- Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT03583424
- Testing
- Carmustine, Cytarabine, Etoposide
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01076270
- Testing
- plerixafor, filgrastim, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Lymphoma, Large B-Cell, Diffuse, Leukemia, Lymphocytic, Chronic, B-Cell
a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
The main purpose of this study is to explore the sequential therapeutic effect and evaluate the safety of anti-CD19 or anti-CD20 CAR-T cells briging HSCT in the treatment of relapse/refractory B cell malignancies.
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma，Malignant
- Trial name
- NCT02846584
- Testing
- CD19 or CD20 CAR T cells briging HSCT
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Southwest Hospital, China
Diffuse Large B-cell Lymphoma
Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL
The purpose of the study is to evaluate feasibility and efficacy of rituximab-bendamustine (R-B)combination in elderly patients affected by diffuse large B-cell lymphoma and defined as frail according to CGA.
- Trial name
- NCT01990144
- Testing
- Bendamustine+Rituximab
- Where
- 52 sites in Italy
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Lymphoma, Peripheral T Cell Lymphoma
Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients
The purpose of this study is to evaluate the effectiveness of circulating DNA from peripheral blood for predicting the prognosis and relapse in DLBCL and PTCL patients.
- Trial name
- NCT03079947
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Acute Leukemia, Acute Lymphoblastic Leukemia
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies).
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT04195633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Hematologic Malignancy
Early Detection and Screening of Hematological Malignancies - SANGUINE
This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM)…
- Trial name
- SANGUINE (NCT05735704)
- Testing
- Blood sampling for HemaChip screening/diagnostic testing
- Where
- 4 sites in Czechia, Greece and 2 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
- Trial name
- NCT00577798
- Testing
- contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B-Cell Lymphoma
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology.
- Trial name
- NCT07188077
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ting YANG
Diffuse Large B-cell Lymphoma, Hodgkin Lymphoma
BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology
Diffuse large B-cell lymphomas (DLBCLs) represent 25 to 30% of adult non-Hodgkin lymphomas in western countries. DLBCLs are aggressive cancer but potentially curable with multi-agent chemotherapy.
- Conditions
- Diffuse Large B-cell Lymphoma, Hodgkin Lymphoma, Metastatic Breastcancer, Non-small Cell Lung Cancer
- Trial name
- BMS_PD-L1 (NCT01660776)
- Where
- 4 sites in France
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL
Safety run-in (part 1): Relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL) Main study (part 2): Relapsed or refractory diffuse large B-cell lymphoma
- Trial name
- NCT04279938
- Testing
- Tinostamustinein, Pembrolizumab, Rituximab
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Diffuse Large B-Cell Lymphoma
Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma
This prospective, non-randomized diagnostic interventional study evaluates cognitive impairment in patients with diffuse large B-cell lymphoma (DLBCL) treated at the Institute of Oncology Ljubljana.
- Trial name
- NCT07443514
- Testing
- Structured Neurocognitive Assessment Battery, Psychometric Questionnaires, CSF Biomarker Analysis
- Where
- Slovenia
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Institute of Oncology Ljubljana
Multiple Myeloma, Non-Hodgkin Lymphoma
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mantle-Cell Lymphoma
- Trial name
- NCT03019666
- Testing
- Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Diffuse Large B Cell Lymphoma
Characterization and Clinical Impact of the Gut Microbiota in Lymphoma
The study is a prospective observational single-center cohort study which compare the gut microbiome of newly diagnosed Diffuse Large B-cell Lymphoma patients with the gut microbiome of healthy controls.
- Trial name
- NCT06161896
- Testing
- Stool samples
- Where
- Denmark
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Lars Møller Pedersen
Lymphoma
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the efficacy and toxicity of Rituximab combined with ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) in the patients with diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT00568815
- Testing
- Rituximab combined with ESHAP
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Fudan University